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ABSTRACT
MICROVASCULAR ENDOTHELIAL CELLS OF THE BOVINE CORPUS 
LUTEUM: A COMPARATIVE STUDY OF THE ESTROUS CYCLE AND
PREGNANCY
by
Jessica A. Cherry 
University of New Hampshire, September, 2006
Endothelial cells derived from the corpus luteum (CLENDOs) exhibit a diverse 
array of characteristics that seemingly complement their wide-ranging properties 
in luteal function and fate. Reproductive status of the animal (i.e., non-pregnant 
vs. pregnant) may contribute to the phenotypic/physiologic diversity of 
microvascular endothelial cells, but information in this regard is limited. Here, 
structural and functional attributes of CLENDOs derived from the estrous cycle 
(Days 9-12) were compared with those of pregnancy (Day 60). Initially, lectin 
binding properties were examined in the cells. Using fluorescent-tagged lectins 
for Bandeiraea simplicifolia I or concanavalin A, flow cytometric analysis 
indicated that lectin-binding on CLENDOs of the estrous cycle did not differ from 
those of pregnancy (P > 0.05). Next, the CLENDOs were exposed to tumor 
necrosis factor alpha (TNF; 50 ng/ml) and/or interferon gamma (IFNG; 30 ng/ml) 
to assess cytokine-induced intracellular signaling [inhibitor kappa B alpha (HcBa)
viii
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degradation and induction of interferon regulatory factor 1 (IRF-1)], production of 
cytokines [TNF and monocyte chemoattractant protein 1 (CCL2)], and cell death. 
Western blot analysis revealed that both types of CLENDOs exhibited a rapid 
decrease in k B a  (P < 0.05), and an equally rapid increase in IRF-1 (P < 0.05), in 
response to cytokine treatment that was not influenced by reproductive status (P 
> 0.05). IFNG stimulated production of TNF by the CLENDOs (P < 0.05), 
revealing that CLENDOs are a source of TNF, regardless of reproductive status 
(P > 0.05). Based on these findings, the ability of TNF to mediate IFNG-induced 
effects was assessed using etanercept, a TNF antagonist. Etanercept inhibited 
direct actions of TNF with respect to CCL2 secretion and IRF-1 induction (P < 
0.05), but did not alter IFNG effects (P > 0.05). Lastly, we determined by 
measuring the incidence of cell death that CLENDOs of the estrous cycle are 
similarly susceptible to TNF- and TNF + IFNG-induced death as CLENDOs of 
pregnancy. These results indicate that several attributes of CLENDOs from the 
estrous cycle are retained by those of early pregnancy, including lectin binding 
properties, activation of specific cytokine-initiated intracellular signals, and the 
instigation of cytokine-induced inflammatory events.
IX




As the world’s population exceeds 6.5 billion people, with estimates 
reaching 10 billion by the year 2050, the demand for food products grows ever 
greater [1]. In 2005, the estimated world consumption of beef and dairy products 
based upon some of the most populous countries (China, European Union, India, 
Russia, and the United States) was 50,000 metric tons and 85,000 metric tons, 
respectively [2, 3]. From this perspective, it would seem essential to increase 
reproductive rates in cattle to meet growing demands for beef and dairy products. 
Unfortunately, fertility rates are currently abysmal in cattle. Conception rates in 
lactating cows are approximately 35-45% [4], Embryo mortality rates stand at 
30-40% [5]. One of the most important aspects of early pregnancy is the 
development and maintenance of a functional corpus luteum (CL), a structure 
within the ovary that secretes the ‘hormone of pregnancy’, progesterone. 
Understanding the cellular and molecular characteristics of CL formation, 
function, and regression within the estrous cycle and throughout pregnancy are 
key components to improving fertility in cattle, thus optimizing beef and dairy 
production to feed the growing world population.
1
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Estrous Cycle
The bovine estrous cycle is approximately 21 days and is dominated and 
controlled by the CL. The estrous cycle is characterized by four distinct phases: 
estrus, metestrus, diestrus, and proestrus. Estrus is the phase during which the 
cow is sexually receptive to the bull. More importantly, it is at the end of this 
phase that ovulation or the release of the oocyte for fertilization occurs [6]. The 
mature, tertiary, or Graafian follicle is the structure that contains the oocyte. The 
follicle is a fluid-filled structure consisting primarily of two cell types, theca and 
granulosa cells [7], The main function of the follicle, along with supporting the 
growth and maturation of the oocyte, is to produce estradiol. Estradiol is 
produced through the joint efforts of both the theca and granulosa cells, which 
carry out this process in what is known as the two-cell theory of estradiol 
production [8, 9]. Theca cells compose the outside of the follicle (theca externa) 
and contain the vasculature (theca interna). Granulosa cells constitute the inside 
cavity of the follicle and are separated from the theca cells and vasculature by a 
basement membrane [7]. Granulosa cells also form a mass surrounding the 
oocyte called the cumulus oophorus, which anchors it to the granulosa cell layer 
within the follicle [10]. As ovulation occurs (approximately 10 hours after the end 
of estrus -  day 0), the oocyte is expelled from the follicle and travels into the 
oviduct to await fertilization [6]. With ovulation, the basement membrane 
separating the theca and granulosa layers of the follicle begins to disintegrate. 
This leads to an invasion of capillaries and new vessel formation extending from 
the theca intema [11]. Also, under the stimulation of luteinizing hormone (LH),
2
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theca and granulosa cells undergo a process known as luteinization, in which the 
cells transform into small and large luteal cells, respectively [12]. As a result of 
all these events, the remnants of the follicle transform into a different structure, 
both physically and functionally, the CL [6, 7].
At the conclusion of estrus, metestrus begins (days 1-4). This phase is 
characterized by the beginning of CL dominance and relatively low circulating 
levels of progesterone and estradiol. It is during this time that the CL matures 
and gradually increases its progesterone production. Estradiol production stems 
from an initial wave of follicle development, but these follicles eventually die by 
atresia due to the prevailing concentrations of progesterone present [6].
The next 10-15 days of the estrous cycle are described as the diestrus 
phase (days 5-18) and can be thought of as the classic period of the luteal phase 
when progesterone production is at its maximum. During diestrus, a second 
wave of follicular development may occur, but the follicles quickly meet the same 
atretic fate as those of the first wave. At approximately day 17, the CL 
undergoes the process of luteal regression if pregnancy does not occur. This is 
classically characterized and attributed to the uterine release of the luteolytic 
agent prostaglandin F2a (PGF2a) [6],
Once the process of luteal regression is initiated, proestrus begins (days 
18-20). At this time, a final wave of follicular growth occurs, which eventually 
results in the dominance of a Graafian ovulatory follicle due to declining 
concentrations of progesterone. Concomitantly, increasing estradiol from the 
dominant follicle signals to the hypothalamus and pituitary gland in the brain.
3
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This triggers increased gonadotropin releasing hormone (GnRH) secretion, which 
leads to a release of LH and follicle stimulating hormone (FSH). A surge in LH 
secretion occurs approximately 12 hours after the peak in estradiol. Together, 
these effects result in the onset of estrus, ovulation (10 hours after the end of 
estrus), and the commencement of CL formation, function, and regression for the 
subsequent estrous cycle [6].
Corpus Luteum
The CL is a transient endocrine tissue that forms within the ovary from the 
remnants of the ovulated follicle. The primary responsibility of the CL is to 
maintain pregnancy, which was first described by Frankel in 1903 who 
discovered that removal of the CL resulted in abortion in rabbits [13,14]. At the 
time, Frankel did not know the identity or nature of the substance responsible for 
maintaining pregnancy. However, 30 years later Allen and Corner described an 
extract from the CL that maintained the pregnancy of ovariectomized rabbits [14, 
15]. The component isolated, subsequently called progesterone, was crystallized 
by Allen and Wintersteiner in 1934 [14,16].
Progesterone is a steroid produced and secreted by the CL. It is primarily 
the ‘hormone of pregnancy’ that influences uterine function, but also has other 
biological targets and effects. Working in concert with estradiol, progesterone 
prepares the genital tract, uterus, and cervix to establish and sustain a 
pregnancy. Progesterone affects the mucosal lining of the genital tract, 
influencing the transport of the oocyte or fertilized ovum in the oviduct, prepares
4
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the uterus for implantation of the embryo and subsequent pregnancy, and 
increases the viscosity of cervical mucus, thereby providing a barrier between the 
uterus and the outside environment [14].
The CL consists primarily of four distinct cell types: large steroidogenic 
cells, small steroidogenic cells, endothelial cells, and fibroblasts. Steroidogenic 
cells make up approximately 30% of the tissue, while the most abundant cell type 
of the CL is the endothelial cell population, comprising approximately 50% of the 
midcycle tissue. Lastly, fibroblasts constitute approximately 10% of the total cell 
population, with immune cells and other unidentified cell types encompassing the 
remaining 10% [17].
As evidenced from the total numbers of endothelial cells, the CL is a 
highly vascularized tissue. The tissue is characterized by having a relatively high 
rate of blood flow (-3 0  mL/min x g of tissue) compared to other tissues (e.g. - 3  
mL/min x g of tissue for the adrenal gland). Also, 65-95% of total ovarian blood 
flow is directed toward the CL during the midcycle phase [18]. The dense 
capillary network constitutes the communication system between the CL and the 
rest of the body; delivering hormones, nutrients, and substrates for steroidogenic 
capacity, and distributing progesterone to its target tissues [18,19], The 
vasculature is essential for the formation, maintenance, and regression of the CL, 
with the opposing processes of angiogenesis and angioregression, respectively, 
in the forefront.
5
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Angiogenesis and Corpus Luteum Formation
Angiogenesis is defined as the generation of new blood vessels through 
the sprouting (migration and proliferation) of existing blood vessels [20]. 
Endothelial cells are mainly responsible for angiogenesis. They must initiate a 
morphogenetic cascade in which extracellular matrix is degraded and in which 
cells migrate toward an angiogenic stimulus, proliferate, and organize into a 
network of new capillaries [21]. The process of angiogenesis occurs rarely in 
adults. It is primarily restricted to pathological conditions such as tumor growth 
and metastasis, and physiological conditions such as wound healing, 
inflammation, and processes pertaining to the female reproductive system (e.g., 
placentation) [22-24].
In the female reproductive system, angiogenesis occurs in the uterus and 
placenta during pregnancy, in addition to the mammary glands. Also, a 
hormonally-regulated, cyclic form of angiogenesis occurs in the uterus and 
ovaries throughout each estrous cycle [20]. In particular, the angiogenic process 
in the ovary is of paramount importance to angiogenesis during the formation of 
the CL. The relatively brief lifespan of the CL provides a useful model for 
understanding the natural angiogenic life cycle (formation, maintenance, and 
regression), important not only for reproduction, but also in terms of 
understanding angiogenesis in tumor growth and regression [24].
Angiogenesis in the ovary is primarily controlled by angiogenic factors 
such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF), and angiopoeitins (Ang 1 and Ang 2). VEGF affects vasodilation,
6
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capillary permeability, and stimulates endothelial cell proliferation. The first 
angiogenic cytokine identified in the ovary was bFGF [25], which is a potent 
endothelial cell mitogen. Ang 1 and Ang 2 are important growth factors in the 
formation of new blood vessels [23, 26].
The angiogenic process in the follicle precedes angiogenesis in the CL, or 
luteal angiogenesis. Ovarian follicles consist primarily of four stages of growth: 
primordial, primary, secondary, and tertiary or Graafian. Primordial and primary 
follicles generally have no vascular network of their own and therefore are not 
associated with any aspects of angiogenesis. As follicles develop an antrum 
(secondary and Graafian follicles), a capillary network is established. There is a 
direct connection between growth and differentiation of these follicles and an 
increased density of blood vessels within the theca cell layers. The vascular 
network is restricted to the theca interna and does not penetrate the basement 
membrane into the granulosa cell layers. The granulosa layers of the Graafian 
follicle, therefore, are avascular. Nutrients and metabolites, including hormones, 
are exchanged via diffusion [19, 23, 24].
At ovulation, the basement membrane separating the granulosa and theca 
layers disintegrates, permitting the invasion of migrating endothelial cells. This 
process, called luteinization, is partially dependent upon angiogenesis. The CL 
undergoes massive growth in a matter of days and is accompanied by an equally 
massive neovascularization. In sheep, for example, new vessel formation in the 
CL is detected within 36 hours of ovulation [27] and more than 50% of the 
proliferating cells in the vascular compartment are endothelial cells [28]. The rich
7
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vascular network of the CL is established to support the dynamic endocrine 
function of the gland [23, 24]. Inadequate vascular formation may play a role in 
ovarian cystic diseases and reduced luteal function [23].
Corpus Luteum Maintenance
The maintenance of the vasculature is of major importance to the midcycle 
CL. Rate of endothelial cell proliferation decreases at this time compared to the 
forming CL, but there is still extensive angiogenesis [23, 29]. Steroidogenic 
capacity of the CL is at a maximum, with the vasculature maintaining an intimate 
relationship with the steroidogenic cells to ensure progesterone synthesis and 
secretion. In fact, each steroidogenic cell is in direct contact with at least two or 
more neighboring capillaries during this period of time [24],
Angioregression and Corpus Luteum Regression
At the onset of luteal regression, a decline in serum progesterone begins, 
followed by a rapid decrease in luteal weight [30]. This rapid loss of tissue is 
accompanied by a reduction of blood flow and loss of vasculature, a process 
known as angioregression, which results in the sharp decrease in numbers of 
endothelial cells. Angioregression is a process usually associated with tissue 
involution, such as scar formation during wound healing. According to Modlich et 
al. (1996) [21], there are two putative mechanisms by which angioregression 
occurs in the CL of the estrous cycle. The first is the loss of endothelial cell tight 
junctions and subsequent detachment of cells from the basement membrane of
8
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the microvasculature. In the guinea pig, early signs of endothelial cell 
degeneration within the CL include loss of tight junctions, protrusion of cells into 
the capillary lumen, and formation of adherens junctions with endothelial cells on 
the opposite side of the lumen [31]. Following detachment of the endothelial 
cells, apoptosis and subsequent removal of the apoptotic bodies from the 
circulation occurs. The second mechanism of angioregression is characterized 
by contraction and occlusion of arterioles and small arteries through proliferation 
of smooth muscle cells surrounding the vessels. Little is known about the 
endocrine events that lead to this mechanism of regression, but vessel occlusion 
suggests that contraction and limited perfusion of the CL may predispose it to 
endothelial cell detachment and deletion [21].
Another aspect of luteal regression is the role of the uterus. The uterus 
has a prominent role in regulating the lifespan of the CL and initiating the process 
of luteal regression in most mammals. Hysterectomy prolongs the lifespan of the 
CL in the cow [32], and luteal structure and function are normally maintained for 
the duration of a pregnancy after removal of the uterus [33]. PGF2a is the 
hormone from the uterus that influences luteal lifespan [34]. Endometrial tissue 
concentrations of PGF2a are maximal during luteal regression. But the strongest 
evidence that PGF2a is involved in luteal regression stems from the fact that 
treating animals with prostaglandin synthesis inhibitors, such as indomethacin, 
blocks spontaneous luteal regression [14]. Also, immunizing cattle to PGF2ot 
prevents spontaneous luteal regression [14]. The luteolytic actions of PGF2a 
differ among species and between in vivo and in vitro models. Proposed
9
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mechanisms of PGF2a action include a large and rapid decline in luteal blood flow 
due to its vasoconstrictive effects, reduced LH receptor expression, and direct 
cytotoxic effects, to name a few [14].
Although the role of PGF2a in luteal regression is important, it cannot 
account for all aspects of luteal regression. For instance, PGF2(X in vitro does not 
inhibit basal progesterone production by steroidogenic luteal cells, leading one to 
believe that other cell types or substances contribute to luteal regression [35],
One widely-recognized aspect of luteal regression in most species is the 
accumulation of immune cells and the onset of immune-mediated events that 
degrade tissue. At the time of luteal regression, T lymphocytes and 
macrophages increase in the CL of the bovine [36, 37], equine [38], murine [39], 
leporine [40], porcine [41], and human [42, 43]. An increase in major 
histocompatibility complex (MHC) class II expression on bovine [44], ovine [45], 
and human [42] steroidogenic cells also suggests immune-mediated 
mechanisms are in place. T lymphocytes and macrophages are important in the 
production of cytokines, and MHC class II molecule expression is essential to 
activating and targeting the immune response.
Activated T lymphocytes and macrophages in the CL produce cytokines, 
particularly interferon gamma (IFNG) and tumor necrosis factor alpha (TNF), 
respectively. IFNG and TNF mRNA expression is detectable in the CL 
throughout the estrous cycle, with TNF levels rising slightly during luteal 
regression [46]. The properties of IFNG and TNF will be discussed further in 
later sections, but in terms of luteal regression, they are anti-steroidogenic,
10
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apoptotic, and increase the expression of MHC molecules in steroidogenic luteal 
cells [47].
Another immunological component of luteal regression is the attraction 
and recruitment of immune cells through chemokines, which facilitate adhesion, 
activation, and chemotaxis of leukocytes. Of particular interest is monocyte 
chemoattractant protein 1 or chemokine ligand 2 (CCL2), a chemokine produced 
by endothelial cells of the CL [48], and known for its recruitment of monocytes, 
basophils, natural killer cells, and T lymphocytes [49]. CCL2 expression has 
been documented in the bovine [50, 51], murine [39, 52], and ovine [53, 54] CL. 
In the bovine CL, CCL2 expression (mRNA and protein) increases during the 
latter half of the estrous cycle (days 12-18) and is accompanied by an 
accumulation of immune cells, indicating CCL2 has a role in immune cell 
recruitment prior to and during luteal regression [51].
Another molecule implicated in luteal regression is the vasoconstrictive 
peptide, endothelin 1 (EDN1). EDN1 is a 21-amino acid peptide produced and 
secreted by endothelial cells [55]. It temporarily inhibits progesterone production 
by the CL in the murine [56], ovine [57, 58], bovine [55], and human [59]. EDN1 
has become a major focus in luteal regression based on its potential role in 
PGF2a-induced luteal regression. During the early luteal phase, when the CL 
does not respond to PGF2a, EDN1 has no effect on progesterone secretion [60]. 
But, during the midcycle and late cycle CL, administration of PGF2a in 
conjunction with EDN1 results in reduced plasma progesterone concentrations, 
which are reversed by an EDN1 antagonist [55, 58, 61]. These results indicate
11
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that EDN1 mediates luteolytic effects of PGF2a from a functional standpoint [62]. 
However, there is no documentation that EDN1 alters the structural integrity of 
the CL [63],
Collectively, vasoactive peptides, such as PGF2a and EDN1, and 
components of the immune system, including T lymphocytes, macrophages, 
cytokines, and chemokines, contribute to luteal regression. Further study is 
required to fully elucidate the signals affecting endothelial cell function within the 
CL during angioregression and subsequent luteal regression.
Corpus Luteum of Pregnancy
Gestation length for a cow is approximately 280 days. The CL is required 
to maintain the pregnancy for the first 200 days, as removal of the CL before this 
time results in termination of the pregnancy [64]. In the ovine CL, the 
morphological characteristics of steroidogenic cells of pregnancy are similar to 
those of the midcycle CL. The ability of steroidogenic cells to produce 
progesterone is maintained, but declines slowly as gestation progresses. Signs 
of cell death in isolated areas appear shortly before parturition. The structural 
and functional changes observed in the CL of pregnancy during regression are 
similar to those of the estrous cycle, with the exception that elimination of dead 
and dying cells occurs over a longer period of time [65].
Mechanistically, the maintenance of the CL of pregnancy is not fully 
understood. Maternal recognition of pregnancy through the secretion of 
interferon tau and inhibition of uterine PGF2a secretion are among the
12
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mechanisms which must occur in order to maintain pregnancy [14]. In cattle, 
luteolytic effects of PGF2a are blocked by an endometrial prostaglandin inhibitor 
or a factor produced by the embryo, bovine trophoblast protein-1 complex, also 
known as embryonic interferon or interferon tau [30, 66, 67]. Additionally, 
preventing an influx of immune cells and the actions of cytokines within the CL of 
early pregnancy appear to be essential. High concentrations of progesterone are 
immunosuppressive and inhibit lymphocyte proliferation and function [47] and 
MHC expression on luteal cells [68], Nevertheless, in-depth knowledge of the 
signals and intracellular mechanisms involved in maternal recognition of 
pregnancy and the maintenance of the CL during pregnancy are not fully 
understood and therefore require further study.
Endothelial Cells of the Bovine Corpus Luteum
Endothelial cells composing the microvasculature of the bovine CL play a 
significant role in the formation, function, and regression of the CL. Angiogenesis 
is essential to the development of the gland; an extensive vascular network must 
be formed in order for the tissue to survive, as an inadequate vasculature is 
associated with reduced luteal function [23]. Maintenance and stability of the 
vasculature is paramount to the endocrine function of the gland, importing 
nutrients, substrates, and hormones, and exporting progesterone to its target 
tissues [18]. The endothelial cell component of the CL is the first to undergo cell 
death during luteal regression, thereby eliminating the blood supply to the tissue 
and dictating its fate [31], The CL is a transient gland, but it is also one of the
13
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
most highly vascularized tissues in the body, with endothelial cells composing 
approximately 50% of the total number of cells [17], Given the crucial roles of 
endothelial cells within the CL, it is important to understand them from both 
morphologic and physiologic standpoints.
There are four distinct types of microvascular endothelial cells of the 
bovine corpus luteum (CLENDOs). Originally, five types were characterized, but 
the fifth was later attributed to be of immature granulosa cell origin, secreting 
progesterone and being unresponsive to LH stimulation [69], The remaining four 
types of CLENDOs are characterized based upon morphology, function, surface 
molecule expression, and cytokeratin 8, 9, and 18 expression [70-75]. All cell 
types maintain contact-inhibited growth and unique morphologic characteristics in 
long-term cultures. Also, all express angiotensin converting enzyme (ACE) and 
internalize acetylated low-density lipoprotein (acLDL), which are hallmarks of 
endothelial cells [70].
Type 1 CLENDOs are isomorphic cells having a cobblestone appearance 
in confluent cultures [70]. They express factor Vlll-related antigen and ACE, both 
of which are localized to the perinuclear area, and they exhibit moderate uptake 
of acLDL. The surface of type 1 cells contains many microvilli and globular 
protrusions in the central area of the apical side of the cell. They also express 
two families of adhesion molecules, neuronal cell adhesion molecule (NCAM- 
140) and epithelial cadherin (E-CAD). These cells stain positively for cytokeratin 
18 (CK18) [71, 74],
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Type 2 CLENDOs are polymorphic cells with numerous nuclei and lacking 
prominent cobblestone morphology [70], They are similar to type 1 cells in that 
they express factor Vlll-related antigen and ACE, and exhibit moderate acLDL 
uptake. Similar to type 1 cells, type 2 cells are NCAM-140 positive, but do not 
express CAD molecules. These cells are also CK18 positive [71, 74].
Type 3 CLENDOs are spindle-shaped cells containing at least one 
prominent intracellular vacuole [70], They have a smooth cell surface with 
processes at the poles, and express factor Vlll-related antigen and ACE 
throughout the cytoplasm. Unlike type 1 and 2 CLENDOs, type 3 cells readily 
uptake acLDL and store it in lysosomes. They do not express NCAM or CAD, 
and they do not contain CK18 filaments [71, 74],
Type 4 CLENDOs are predominantly round cells with no intracellular 
vacuoles [70]. They have short filipodia radiating around the cell margins.
Similar to type 3 cells, type 4 cells express factor Vlll-related antigen and ACE 
throughout the cytoplasm, acLDL uptake is abundant in lysosomes, they do not 
express NCAM or CAD, and they are CK18 negative [71, 74],
Expression of the intermediate filament CK18 may be one of the more 
important distinctions among the unique classifications of endothelial cell types. 
The cytokeratin 18 positive (CK18+) phenotype is rare within CLENDOs of the 
bovine CL [70, 76, 77]. Morphologically and functionally, CK18+ CLENDOs are 
different from the more abundant cytokeratin 18 negative (CK18-) cells, but 
appear morphologically similar to CK18+ endothelial cells of the bovine aorta 
[76]. Factor VIII expression is 5-fold lower in CK18+ CLENDOs than CK18-
15
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CLENDOs, and acLDL uptake is 10-fold lower. Functionally, CK18+ and CK18- 
CLENDOs differ in cytokine production in response to TNF stimulation. TNF- 
induced granulocyte-macrophage colony-stimulating factor (GM-CSF) is 
expressed only by CK18- CLENDOs, and TNF-induced ‘regulated on activation, 
normal T  cell expressed and secreted’ (RANTES) mRNA levels are 200 times 
higher in CK18- CLENDOs than CK18+ CLENDOs [75], Conversely, CK18+ 
CLENDOs express mRNA for prostaglandin E2 (PGE2) and PGF2a receptors, 
while CK18- CLENDOs do not [78].
From the aspects of angiogenesis and angioregression, expression of 
angiopoeitins (Ang 1 and Ang 2) among the different CLENDO types is 
interesting. Both CK18+ and CK18- CLENDOs do not contain Ang 1 mRNA, and 
only CK18- contain Ang 2 mRNA [79], Ang 1 and Ang 2 mRNA are present in 
the developing and functional CL [26]. Wulff et al. (2000) localized Ang 1 
expression in steroidogenic and endothelial cells throughout the human CL [80], 
but its localization within the bovine CL has not been reported. Although its 
source is unknown, Ang 1 stimulates sprouting and maturation of blood vessels 
in vitro, while Ang 2 is a competitive inhibitor, binding to the same tyrosine kinase 
with immunoglobulin and epidermal growth factor homology domains (Tie-2 
receptor), but not activating the intracellular signals of angiogenesis. Also, levels 
of Ang 2 are elevated during luteal regression, suggesting that Ang 2 has a role 
in angioregression [26, 63].
The endothelium is a major target for cytokines in most tissues.
Endothelial cells serve as part of the barrier or ‘gatekeeper’ between the blood
16
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stream and the tissues, determining the traffic and action of cells and molecules 
within the body [81]. As previously mentioned, there are large numbers of 
endothelial cells in the CL and thus endothelial-immune cell interactions are 
reasoned to be important in luteal function. Treatment of CLENDOs with the 
cytokine IFNG alters their morphology, which might lead to important functional 
alterations. For instance, type 1 -4 cells become flattened and enlarged upon 
IFNG treatment [63]. Type 3 cells form large, lipid-filled vacuoles, possibly 
indicating the onset of senescence [73]. IFNG also elevates CAD levels in type 1 
cells, and disturbs actin structure and reduces fibronectin content in type 1, 3, 
and 4 cells [72]. As a result, IFNG could lead to an anti-proliferative effect, which 
is observed in type 1-4 CLENDOs [73]. Also, stimulation of CLENDOs with TNF, 
IFNG, or TNF + IFNG results in increased secretion of CCL2, suggesting a role 
for immune-mediated mechanisms in luteal function [48]. Similarly, placement of 
CLENDOs in co-culture with activated immune cells also results in increased 
CCL2 secretion [82].
In summary, the four types of CLENDOs within the bovine CL are 
morphologically and physiologically unique, but contribute to the formation, 
function, and regression of the microvasculature. Important distinctions based 
upon CK18 expression, PGF2a receptor presence, and response to cytokines 
reveal that further study is required to determine the physiologic significance of 
these cell types during different phases of CL function, both during the estrous 
cycle and pregnancy.
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Interferon Gamma
Interferons were first characterized in 1957 by Isaacs and Lindenmann as 
substances that interfere with viral replication [83]. Their antiviral capabilities led 
to their discovery, but it is now known that interferons are one of the main 
classes of cytokines naturally produced in the body with far-reaching implications 
beyond the fight against disease. Specifically, interferons influence the overall 
function of the immune system and therefore the body as a whole.
There are two major groups of interferons, type I and type II, which are 
classified primarily by structural homology and receptor binding specificity. Type 
I interferons are separated into two main types, IFNa and IFNp [84], but also 
include IFN5, IFNe, IFNk , IFNx, and IFNco [85]. IFNa is a family of related 
proteins primarily produced by leukocytes, and IFNp is a single protein produced 
mainly by fibroblasts. The type I interferons are widely expressed and largely 
induced in response to viral infections [84, 86]. In contrast, IFNy (IFNG) is the 
only type II interferon. It is called an interferon solely on the merits of its antiviral 
effects, but it is a completely different molecule from the other interferons both in 
structure and action [87].
IFNG was originally referred to as ‘immune interferon’ or ‘immune-induced 
interferon’ because it is produced by lymphocytes following antigenic stimulation; 
whereas ‘classical interferons’ are molecules produced by leukocytes or non­
lymphoid cells [88, 89], As the old nomenclature describes, IFNG is primarily 
activated by immune and inflammatory stimulation. It was thought to be 
produced solely by T lymphocytes through MHC class I and II antigenic
18
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stimulation and by natural killer cells through TNF and macrophage cofactor 
stimulation. Recently however, professional antigen presenting cells such as 
monocytes/macrophages have also been identified as sources of IFNG [90, 91].
IFNG elicits major effects on cells of the immune system including 
regulating MHC class I and II expression on mononuclear phagocytes, 
endothelial cells, and epithelial cells. IFNG also activates and regulates the 
differentiation and function of monocytes/macrophages (hence IFNG once being 
known as ‘macrophage-activating factor’ [92]), and regulates B cell functions 
such as immunoglobulin production and isotype/class switching [84, 90, 91].
IFNG has a major role in inflammatory response, most notably through its 
synergistic action with TNF. The synergistic actions of IFNG/TNF will be 
discussed in detail later, but briefly, IFNG increases the expression of TNF 
receptors on the surface of cells [93, 94], and enhances TNF production by 
macrophages in an endotoxin (lipopolysaccharide)-induced inflammatory 
response [90],
The wide variety of IFNG actions is perhaps due to the relatively 
ubiquitous expression of IFNG receptor throughout the body [90, 95]. The IFNG 
receptor (IFNGR) is a transmembrane, multi-chain structure composed of two 
ligand binding units, IFNGR1, and two signal transduction units, IFNGR2 [84, 91] 
(Fig. 1). The extracellular domain of the receptor is the ligand binding site, while 
the intracellular domain functions in signal transduction. IFNGR1 is constitutively 
expressed and plays the critical role in receptor-binding recognition. In contrast, 
IFNGR2 has the major role of signal transduction and is the limiting factor in
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IFNG action. It is also constitutively expressed, but at low levels and under tight 
regulation [84]. Upon dimerization of the IFNG ligand subunits [96], subsequent 
binding to IFNGR1 occurs, resulting in IFNGR1 and IFNGR2 association [84]. 
The IFNG receptor alone is incapable of inducing an intracellular signal. 
Therefore, it associates with Janus tyrosine kinases (enzymes named for the 
Roman God Janus who had two faces). The Janus kinases (Jaks) have two 
faces/sites, one a binding site to associate with the IFNG receptor and the other 
a catalytic site with tyrosine kinase phosphorylation capabilities [97, 98]. In 
particular, IFNGR1 associates with Jak1 and IFNGR2 with Jak2 [84] (Fig. 1). 
These Jaks, in turn, interact with signal transducers and activators of 
transcription (Stat) signaling cascades.





Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
When the IFNGR1 and IFNGR2 subunits interact, Jak1 and Jak2 are 
activated by Jak2 autophosphorylation and subsequent transphosphorylation of 
Jak1 [91] (Fig. 1). The activation of Jak1 attracts a particular Stat, S tatl, from 
the cytoplasm to associate with the receptor complex [99] (Fig. 1). Upon 
association, Statl is phosphorylated and homodimerizes [100] to become 
gamma interferon activated factor (GAF) [101] and translocates to the nucleus 
(Fig. 1). In the nucleus, GAF targets gamma interferon activated site (GAS) 
elements on DNA to initiate or suppress transcription of IFNG-regulated genes 
(Fig. 1), such as the transcription factor interferon regulator factor 1 (IRF-1) [85].
IRF-1 is a member of an ever growing family of transcription factors known 
as interferon regulatory factors (IRFs). It was first characterized as a regulator of 
virus-inducible enhancer-like elements of the human IFNp gene [102]. IRF-1 is 
expressed at low levels in unstimulated cells but is greatly induced upon 
stimulation with cytokines, such as IFNG and TNF [103]. IRF-1 activation is 
important in the development of T lymphocyte subsets (CD4+ and CD8+) [104] 
and is capable of inducing typical IFNG functions, such as increasing MHC 
expression [103].
The most crucial action of IRF-1 is its ability to activate transcription and 
interact with transcription factors, such as nuclear factor kappa B (NF-kB). IRF-1 
as a transcription factor controls the expression of many different target genes, 
including cyclooxygenase 2 [105], an enzyme responsible for prostaglandin 
production in inflammation, and caspases 1 and 7, which regulate apoptosis [96].
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The role of IRF-1 in apoptosis can be either pro- or anti-apoptotic. IRF-1 
activation alone does not lead to cell death unless accompanied by the actions of 
certain cytokines (fibroblast-associated (Fas) ligand and TNF + IFNG) or as 
result of a pathologic condition [103]. The pro-apoptotic actions of IRF-1, 
particularly induced by treatment of cells with TNF + IFNG, are of interest in the 
present study. Furthermore, IFNG-activated IRF-1 inhibits TNF-induced NF-kB 
activation, which is a protective, anti-apoptotic pathway [106]. Conversely, IRF-1 
is thought to contribute to cell survival in certain physiologic situations [103].
In the bovine CL, IFNG mRNA is detectable at all stages of the estrous 
cycle [46], Penny and co-workers (1999) reported the presence of IFNG mRNA 
around the time of luteal regression, which coincided with an infiltration of T 
lymphocytes, the primary source of IFNG [36]. In addition, IFNG mRNA declines 
during late diestrus (day 18) and at 1h post PGF2a-induced luteal regression [46]. 
Currently, there are no protein or absolute quantitative mRNA data regarding 
IFNG expression in the bovine CL.
Despite the relative lack of information available about IFNG expression, 
there are several postulated roles of IFNG in the bovine ovary. IFNG enhances 
Fas ligand (FasL)-induced killing of granulosa, theca [107], and luteal cells [108]. 
IFNG augments the expression of MHC class II molecules on bovine 
steroidogenic luteal cells [109] and microvascular endothelial cells of the CL 
(type 2 in particular) [110]. Along with promoting immune response mechanisms, 
IFNG enhances the production of PGF2a by bovine luteal cells and inhibits LH- 
stimulated progesterone production [111].
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IFNG signaling in bovine luteal cells is transduced by the Jak-Stat 
pathway, but does not alter NF-kB expression. S ta tl, but not kB a, protein levels 
are significantly increased following IFNG treatment, indicating signaling through 
the Jak-Stat, but not NF-kB pathway. Also, IFNG influences the transcription and 
translation of IRF-1 [112].
Tumor Necrosis Factor Alpha
TNF was first described as an endotoxin-induced factor produced by 
macrophages [113] that causes necrosis of tumors [114]. For several years, the 
focus of TNF research centered on cancer biology [115], Since the time of its 
characterization however, TNF is now known to regulate immune responses 
(inflammatory and apoptotic pathways), cellular proliferation and differentiation, 
tumorigenesis, and viral replication [116,117]. Additionally, as TNF has a major 
role in regulating immune cell activity, it is also involved in pathological 
conditions, including autoimmune disorders, such as rheumatoid arthritis, irritable 
bowel syndrome [118], and psoriasis [119].
TNF is a cytokine produced primarily by macrophages, but also by B and 
T lymphocytes, mast cells, fibroblasts, endothelial cells, and neuronal tissue. It is 
a 26-kDa transmembrane protein cleaved by the metalloprotease TNF-alpha- 
converting enzyme (TACE) to a 17-kDa soluble form. TNF is arranged in stable 
homotrimers and is active in membrane-bound or soluble forms [117, 120].
TNF exerts its biological functions via the TNF receptor superfamily, 
particularly TNF-receptor 1 (TNF-R1) and TNF-receptor 2 (TNF-R2). Membrane-
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bound TNF readily activates both receptors, while soluble TNF predominantly 
signals through TNF-R1. TNF-R1 is constitutively expressed in most tissues, 
while TNF-R2 is highly regulated and restricted to cells of the immune system. 
Both receptors contain a pre-ligand-binding assembly domain (PLAD) that results 
in receptor trimerization upon activation by TNF [120],
The intracellular domains of the TNF receptors are different and of 
functional importance. TNF-R1 contains a protein-protein interaction domain 
referred to as a death domain (DD) that is crucial to the death-inducing activity of 
the receptor [120]. Upon binding of TNF, an inhibitory protein called the silencer 
of death domain (SODD) is released [117] (Fig. 2). The DD can then recruit 
other proteins containing DD, such as TNF receptor-associated death domain 
(TRADD). TRADD in turn attracts Fas-associated death domain (FADD), which 
initiates signaling events through caspase activation that lead to apoptosis [121] 
(Fig. 2).
TRADD also attracts TNF-R-associated factor 2 (TRAF2), which can lead 
to anti-apoptotic pathways. TRAF2 binding to TRADD results in the production of 
the anti-apoptotic protein cellular inhibitor of apoptosis protein-1 (clAP-1) (Fig. 2). 
Also, TRAF2 attracts NF-icB-inducing kinase (NIK) and receptor interacting 
protein (RIP), which separately attract inhibitor of kB kinase (IKK), activating NF- 
kB (Fig. 2). Unlike TNF-R1, TNF-R2 does not signal through a DD. Instead, it 
directly recruits TRAF2, and signals through the NF-kB pathway, or induces the 
expression of membrane-bound TNF which subsequently activates TNF-R1 [117, 
121].
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Figure 2. TNF signaling pathway.
caspase
activation APOPTOSIS
As mentioned, a commonality between TNF-R1 and TNF-R2 is their ability 
to induce NF-kB activation [122]. NF-kB is a transcription factor located in the 
cytoplasm associated with an inhibitor complex, inhibitor kB (IkB), in an 
unactivated state. Upon activation of IKK, IkB is phosphorylated and 
relinquishes NF-kB, which then translocates to the nucleus and induces gene 
expression (Fig. 2). NF-kB activation increases expression of inflammatory 
proteins [123], and interestingly, anti-apoptotic molecules such as clAP-1 [121], 
cellular FLICE-like inhibitory protein (cFLIP), and B-cell leukemia/lymphoma 2 
(Bcl-2) [124] (Fig. 2). The latter products of NF-kB activation lead to an 
interesting paradigm of TNF receptor signaling, particularly TNF-R1. Ligand
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binding can lead to both pro-apoptotic and anti-apoptotic pathways via activation 
of DD-associated proteins. Also, the absence or inhibition of NF-kB activity 
results in increased cellular susceptibility to TNF-induced apoptosis, whereas 
activation of NF-kB protects against it [121]. These pro- and anti-apoptotic 
actions of TNF are of particular interest in the current study.
In the CL, the presence and localization of TNF and its receptors have 
been extensively studied in numerous species. In the rabbit, lipopolysaccharide- 
induced TNF production in the regressing CL is elevated, but also present in the 
early CL (day 5) [125]. There are large numbers of macrophages in the 
regressing CL of the rabbit, suggesting that macrophages are the source of TNF. 
But TNF secretion by the early CL and the scarcity of macrophages indicate that 
other cell types within the rabbit CL produce TNF [125]. Recent studies 
describing TNF secretion in the porcine CL have further added to the confusion 
of the cellular sources of TNF within the CL.
TNF protein is present in the porcine CL during the estrous cycle and 
pregnancy with no difference between the two physiologic states [126].
According to Hehnke-Vagnoni and co-workers (1995) [126], TNF is localized to 
the endothelial cells of functional CL, while macrophages are rarely seen and not 
associated with TNF staining. No TNF was detected in CL undergoing functional 
luteal regression [126]. In contrast, Zhao and co-workers (1998) [127] report that 
macrophages are the major source of TNF in the porcine CL. TNF is co­
localized to cells that also stain positively as macrophages, whereas endothelial 
cells consistently lacked TNF staining. A bioassay of the individual cell
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populations incubated with lipopolysaccharide similarly revealed macrophages as 
the major source of TNF secretion in the porcine CL [127]. In the pig, TNF 
receptors are present and functional within the CL throughout the estrous cycle 
and early pregnancy. Receptor concentration increases in the late luteal stage of 
the estrous cycle (day 15) compared to the CL of pregnancy on the same day, 
suggesting a role for TNF in luteal regression [128]. TNF also induces apoptosis 
of porcine luteal cells [129], TNF receptors are localized to small luteal cells 
(small steroidogenic and endothelial cells) of porcine CL [130], implying a 
possible autocrine action of TNF on endothelial cells of the CL.
In the bovine CL, TNF protein increases around luteal regression, days 
13-18 of the bovine estrous cycle, but there is no difference in TNF mRNA 
expression throughout the estrous cycle [131]. Intraluteal TNF concentration 
increases after progesterone begins to decline, but there is no increase in 
systemic concentrations of TNF [132], TNF-R1 mRNA levels are greatest in the 
early luteal phase (days 3-7) [131]. In CLENDOs, TNF receptor protein 
expression is seen in type 3 CK18- CLENDOs of the estrous cycle having two 
binding affinities (low and high) for TNF. TNF-R1 mRNA is expressed by the 
CLENDOs, but the levels are less than the CL as a whole [133],
In the bovine CL of pregnancy, TNF mRNA is present in equal amounts 
throughout gestation, but TNF receptor protein expression is higher during the 
early and late stages of pregnancy as compared to the middle of pregnancy 
[134].
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TNF has a variety of effects on the CL. In vitro, TNF alone and in 
combination with IFNG increases PGF2a synthesis by bovine luteal cells [135]. 
TNF does not affect basal progesterone production but does suppress LH- 
stimulated progesterone production. In vivo, low concentrations of TNF promote 
luteal regression and shorten the estrous cycle, whereas high concentrations 
activate CL function and prolong the estrous cycle in cattle [136]. A low dose of 
TNF (1 pg) stimulates PGF2a production but does not affect progesterone 
production. Conversely, a high dose of TNF (10 pg) stimulates progesterone and 
the luteotrophic PGE2 [136]. These divergent effects of TNF highlight its 
potential role in regression of the CL, suggesting different concentrations could 
stimulate either pro- or anti-apoptotic pathways.
TNF promotes cell proliferation in rat ovarian theca-interstitial cells [137], 
yet induces apoptotic cell death in bovine CLENDOs [138, 139], TNF-R1 mRNA 
expression is higher in endothelial cells of the CL than steroidogenic cells, and 
TNF induces time- and dose-dependent death in endothelial cells [138]. It is 
hypothesized that progesterone within the CL regulates cell survival in relation to 
TNF-induced death. Physiologic levels of progesterone prevent TNF-induced 
death of CLENDOs [138], and steroidogenic cells, which produce progesterone, 
are consistently protected against TNF-induced death [138]. Other luteolytic 
actions of TNF include increasing endometrial production of PGF2a [140], 
enhancing MHC class I expression on bovine luteal cells [135], and inhibiting 
luteotrophic estradiol production in the porcine CL [141].
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With regard to the CL of pregnancy, TNF plays similar roles in its 
regression as mentioned for the CL of the estrous cycle, but TNF also potentially 
contributes to the maintenance of the CL of pregnancy. In vitro, TNF stimulates 
PGE2 and PGF2« production, which increase progesterone output by luteal cells. 
The output of PGE2 and PGF2a by the CL at day 200 of gestation is greater than 
at day 14 of the estrous cycle, and progesterone production from day 200 is 
increased by PGE2 but not LH. Also, there are higher numbers of PGE2 
receptors in pregnant versus nonpregnant ewes [142], and large luteal cells are 
known to produce progesterone in response to PGE2 [143]. Therefore, TNF 
stimulates the production of PGE2 and PGF2a by the CL of pregnancy, and 
indirectly increases its progesterone production [144].
Synergy of Tumor Necrosis Factor Alpha and Interferon Gamma
TNF and IFNG are two cytokines that influence the actions of each other. 
The synergistic action of TNF and IFNG was first documented as a cytotoxic 
effect in which the two cytokines in combination were more potent than either 
cytokine alone [145]. This synergy of TNF and IFNG to induce cell death has 
been documented for rat hepatocytes [146], mouse luteal cells [147], and bovine 
luteal cells [135, 148]. Originally, the synergistic action of TNF and IFNG was 
attributed to the regulation of TNF receptors by IFNG. That is, IFNG induces the 
synthesis of TNF receptors, resulting in an upregulation of both types of TNF 
receptors (TNF-R1 and TNF-R2) on cells [94]. The enhancement of TNF 
receptors, and thus TNF binding, was thought to be the mechanism for the
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cytotoxic effect [93, 149, 150]. However, others contend that IFNa and IFNp do 
not have a significant effect on TNF receptors, but nonetheless enhance the 
cytotoxic activity of TNF [151]. Alternatively, intracellular signaling might account 
for the synergistic action of TNF and IFNG.
Intracellular signaling has a prominent role in regulating the effects of 
cytokines. Statl activation by IFNG and NF-kB activation by TNF are necessary 
for the induction of genes potentially important for mediating their cooperative 
activities, such as IRF-1. TNF and IFNG independently and synergistically 
promote the expression of IRF-1 [152]. IRF-1 inhibits NF-KB-mediated activation 
of cell survival signals through modulation of NF-kB transcriptional activity [106]. 
Therefore, IRF-1 induction by TNF and IFNG alone or synergistically might 
prevent activation of the anti-apoptotic NF-kB pathway, leading to cell 
death/apoptosis (Fig. 3).
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Other mechanisms by which TNF and IFNG promote death and 
destruction of tissues include augmenting Fas-mediated apoptosis and 
enhancing elements of an immune response. In the ovary, TNF and IFNG 
potentiate Fas-mediated apoptosis of granulosa and luteal cells [108, 153, 154], 
increase MHC class I [155] and intercellular adhesion molecule I (ICAM-1) 
expression [156], and enhance the secretion of CCL2 [48, 82,157].
Lectins
Lectins are a class of non-immunologic proteins and glycoproteins that 
bind specifically to carbohydrates. They were originally referred to as 
hemagglutinins or phytoagglutinins because they originate from plant extracts
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and have the ability to agglutinate erythrocytes [158]. Interestingly, ricin, the 
deadly toxin occasionally used by extremist groups in terrorist plots, was the first 
isolate from a plant, the castor bean (Ricinus communis), to show properties of 
hemagglutination. ‘Lectin’ comes from the Latin term legere, meaning to pick out 
or choose. The name lectin was chosen due to the blood-type specific 
hemagglutination exhibited by some of the extracts from plants [159]. For 
example, the extract from Griffonia simplicifolia (also known as Bandeiraea 
simplicifolia) has almost exclusive specificity for blood type B [160]. The name 
lectin now encompasses any non-immune origin, sugar-specific agglutinin, 
regardless of source (plant, animal, microbial) and blood type specificity [158]. 
Lectins from sources other than plants, such as animals, viruses, bacteria, 
protozoa, etc., are rarely used in the more common applications of lectins [161], 
which include precipitating carbohydrate-containing macromolecules, and 
agglutinating plant and animal cells along with bacteria and yeast [162],
Because lectins bind carbohydrate moieties on cell surfaces, they can be 
inhibited by sugars for which they are specific. For example, concanavalin A 
binds to D-mannose/D-glucose [163, 164]. Placing D-glucose in solution with 
concanavalin A inhibits binding of concanavalin A to cell surfaces.
Concanavalin A (ConA), isolated from the jack bean (Canavalia 
ensiformis) [165], is the most extensively studied lectin [163]. It serves as a 
structural probe for carbohydrates in solution and on cell surfaces. It is also a 
lymphocyte mitogen, anticancer agent, reagent for differentiating normal from 
malignant cells, and model for antibody-antigen reactions [158, 164], ConA is an
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exclusively protein lectin. It is one of the few lectins not covalently bound to a 
carbohydrate (glycoprotein), making it similar to wheat germ agglutinin (WGA), 
another protein lectin [164].
Bandeiraea simplicifolia I (BS-I), also known as Griffonia simplicifolia I, 
isolated from Bandeiraea simplicifolia seeds, is a type B blood specific 
hemagglutinin [166]. Bandeiraea simplicifolia seeds yield two lectins with 
different sugar-binding specificity, BS-I binds D-galactose, while BS-I I binds 2- 
acetamido-2-deoxy-D-galactose. Unlike ConA, BS-I is a glycoprotein, binding 
specifically to a-D-galactose [164].
Lectins are classically used for cell agglutination purposes. They primarily 
interact with carbohydrate moieties on the cell surface in the form of glyco­
proteins and glycolipids. However, lectins can also interact with glycoproteins 
and glycolipids within organelles such as chloroplasts and mitochondria, if the 
cell has been permeabilized. Additionally, lectins have been used as membrane 
structural probes, determining the localization and function of carbohydrates on 
the plasma membrane or intracellular membranes [163]. Of relevance to the 
present study is their ability to be labeled, with either radioisotopes or 
fluorophores, to quantitatively assess lectin binding sites on cells. Also of 
significance to the present study is the use of lectins coupled to certain media, 
such as magnetic beads, to purify specific cell populations.
In reproductive physiology, lectins are used to purify mixed cell 
populations. In particular, the lectin BS-I has been used to isolate CLENDOs 
from a mixed population of cells from the bovine CL containing small and large
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steroidogenic cells, fibroblasts, pericytes, immune cells, and endothelial cells [62, 
167-171], CLENDOs bind the lectins BS-I and ConA, among others. BS-I is a 
constitutive endothelial cell marker throughout the developmental stages of the 
CL, while ConA exhibits a broad binding expression pattern throughout the ovary 
[20], But other authors have indicated that BS-I binding differs between 
CLENDO phenotypes and CLENDOs of the estrous cycle versus CLENDOs of 
pregnancy [172], These conflicting data indicate further study of lectin 
expression in CLENDOs is required.
Also of interest to the present study is lectin expression with regard to 
angiogenesis. Particularly, endothelial phenotype, with respect to lectin 
expression, is thought to change in migrating versus contact-inhibited cultures of 
bovine aortic endothelial cells [173]. As the CL is a tissue that undergoes 
angiogenesis, maintenance of the vasculature, and angioregression, changing 
lectin expression throughout the course of the estrous cycle and pregnancy could 
be of significance to the overall processes of luteal formation, function, and 
regression.
Objectives and Hypotheses
To our knowledge, there are few studies that directly compare CL of the 
estrous cycle versus pregnancy, and even fewer that assess the luteal 
vasculature. Therefore, the current study set out to compare structural and 
functional attributes of CLENDOs of the estrous cycle with those of pregnancy to 
determine if reproductive status contributes to the diversity of microvascular
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endothelial cells. The parameters assessed were lectin binding, Ik B cx 
degradation, IRF-1 expression, TNF and CCL2 production and secretion, and 
apoptosis. The current hypotheses are as follows: 1) There is no difference in 
lectin expression between CLENDOs of the estrous cycle and pregnancy. 2) 
There is no difference in TNF-induced k B a  degradation between CLENDOs of 
the estrous cycle and pregnancy. 3) There is no difference in TNF- and IFNG- 
induced IRF-1 expression between CLENDOs of the estrous cycle and 
pregnancy. 4) CLENDOs are a source of TNF. 5) There is no difference in 
IFNG-induced TNF secretion between CLENDOs of estrous cycle and 
pregnancy. 6) There is no difference in cytokine-induced production of CCL2 
between CLENDOs of the estrous cycle and pregnancy. 7) TNF and TNF + 
IFNG are cytotoxic to CLENDOs of the estrous cycle and pregnancy, while IFNG 
alone is not.
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CHAPTER II
MICROVASCULAR ENDOTHELIAL CELLS OF THE BOVINE CORPUS 
LUTEUM: A COMPARATIVE STUDY OF THE ESTROUS CYCLE AND
PREGNANCY
Introduction
The corpus luteum (CL) is a temporary endocrine gland that forms within 
the ovary following ovulation and contributes to estrous/menstrual cycle regularity 
and the establishment and maintenance of early pregnancy [14]. Aside from its 
transient nature, an intriguing aspect of the CL is its adaptable lifespan. In 
domestic livestock, the CL remains functional for as few as 15-18 days to as 
many as 200-300 days depending upon species and reproductive status of the 
animal [174]. In the bovine for instance, the CL develops, functions, and begins 
to regress within 17-18 days of the estrous cycle, or it can have a functional 
lifespan of more than 200 days during pregnancy [64]. Similarly, the functional 
lifespan of ovine CL varies from 15-16 days during the estrous cycle to 
approximately 50 days during pregnancy [175]. In fact, in most placental 
mammals the continuation of luteal function extends well beyond the 
estrous/menstrual period and is required for the establishment and maintenance 
of pregnancy for a significant portion of the first trimester [14], Thus, plasticity of 
the CL would appear to be critical to its function: alterations in cellular
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composition and hormonal responsiveness permit adaptations to reproductive 
status (i.e., estrous cycle -> pregnancy).
Historically, relatively few studies have directly assessed attributes of the 
CL of the estrous cycle versus the CL of pregnancy. Those that have compared 
the two physiologic states have primarily focused on the composition and 
physiology of the steroidogenic cell populations. For example, in the ovine, 
corpora lutea of the estrous cycle and of pregnancy are of similar size, weight, 
and cellular composition [65, 175,176], Steroidogenic cells in both types of 
corpora lutea comprise about 60% of the tissue [65], and have comparable 
volume density, cytoplasmic to nuclear ratio, cell number/mm3, and cell volume 
[175]. Yet the “small” steroidogenic cells of corpora lutea of pregnant ewes are 
larger, and both the “small” and “large” cells are less responsive to luteinizing 
hormone (LH) stimulation than the comparable steroidogenic cells of corpora 
lutea from nonpregnant ewes [176]. A similar distinction in LH response is also 
observed in steroidogenic cell populations of bovine corpora lutea [177]. 
Progesterone concentration in corpora lutea of pregnant ewes is greater than in 
corpora lutea of non-pregnant ewes, even though no differences exist in luteal 
weight or circulating concentrations of progesterone [176]. In the bovine, 
however, higher progesterone concentrations exist in the milk of pregnant versus 
nonpregnant cows [178],
From the standpoint of luteal regression, a few studies have compared 
key components of the process in corpora lutea under different physiological 
states (nonpregnant vs. pregnant), such as prostaglandin receptor expression
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and immune function. Wiepz and colleagues (1992) indicate that while ovine 
corpora lutea possess 7-10-fold more receptors for prostaglandin F2a (PGF2a) 
than prostaglandin E2 (PGE2), regardless of reproductive status, there are 
generally more of both types of receptors in corpora lutea of pregnant than 
nonpregnant ewes [142]. PGF2ct is a known luteolytic agent [34], while PGE2 is 
luteotrophic [136], delays luteal regression, and suppresses PGF2a actions [14]. 
Therefore, it appears that continuation of the CL into pregnancy in the ewe is not 
due to downregulation of prostaglandin receptors, thereby rendering the CL 
unresponsive to the luteolytic PGF2h. Instead, other mechanisms must contribute 
to luteal regression and be suppressed or inactive for the CL to maintain its 
structure and function throughout pregnancy. One such possibility is the role of 
the immune system in luteal regression. In the ovine, bovine, and equine, 
expression of major histocompatibility (MHC) class II molecules is diminished in 
corpora lutea of pregnant animals compared to cyclic animals [38, 44, 45], This 
suggests that mechanisms of immune suppression exist within the CL of 
pregnancy to sustain its function. Consistent with these observations, luteal 
regression at the end of pregnancy in the ovine is reported to be similar to that of 
the estrous cycle (e.g., characterized by endothelial cell loss and immune cell 
infiltration [175]), but occurs over an extended period of time (i.e., several weeks 
[179]) in the postpartum ewe [65].
The aforementioned studies focus almost exclusively on the steroidogenic 
cell population of the CL, but the CL is comprised not only of “small” and “large” 
steroidogenic cells, but also endothelial cells, fibroblasts, and immune cells [17].
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Endothelial cells make up about 50% of the midcycle CL [17] and are vital in the 
formation, function, and regression of the tissue. Angiogenesis is essential to the 
development of the gland, as an inadequate vasculature is associated with 
reduced luteal function [23], Stability of the vasculature is paramount to the 
endocrine function of the gland, importing nutrients, substrates, and hormones, 
and conveying progesterone to its target tissues [18]. Endothelial cells of the CL 
are among the first cells to undergo apoptosis during luteal regression, thereby 
eliminating the blood supply to the tissue and dictating its fate [31]. Since 
endothelial cells are the first cell type to be eliminated during regression of the 
CL, their maintenance in the CL of pregnancy would lead one to believe that 
microvascular endothelial cells of the CL (CLENDOs) of the estrous cycle and of 
pregnancy differ. Potential physical and functional differences in CLENDOs 
could help explain how the CL of the estrous cycle has a defined lifespan of 17- 
18 days, whereas the CL of pregnancy is maintained for as many as 200 days.
To our knowledge, there is currently only one study in which bovine 
CLENDOs of the estrous cycle and pregnancy have been directly compared. 
Plendl et al. (1996) reported different expression of surface carbohydrates 
(lectins) based on reproductive status and cellular morphology in bovine 
CLENDOs [172]. Specifically, CLENDOs of pregnancy of the cobblestone 
phenotype (versus arcuate) have significant binding capacity for the lectins 
Bandeiraea simplicifolia I (BS-I), wheat germ agglutinin (WGA), and concanavalin 
A (ConA) compared to the estrous cycle [172]. Also, spontaneous angiogenic 
activities, such as cellular migration in band-like structures and formation of ring
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like-structures in vitro, are observed exclusively in CLENDOs of pregnancy [172]. 
These results indicate that cellular recognition markers, such as lectins, differ 
between CLENDOs of pregnancy and the estrous cycle. Physical differences 
such as these infer different functions of these cells within the microvasculature, 
particularly with regard to angiogenic capabilities.
Considering the relatively few studies which have directly compared CL of 
the estrous cycle versus pregnancy, and even fewer studies assessing the 
diversity of the luteal vasculature, the current study determined if reproductive 
status contributes to the diversity of luteal microvascular endothelial cells. Lectin 
binding was compared between CLENDOs of the estrous cycle and pregnancy 
as a basis of physical/morphological attributes. Responsiveness to the cytokines 
tumor necrosis factor alpha (TNF) and interferon gamma (IFNG) were assessed 
as functional attributes to determine if immune mechanisms are similar between 
CLENDOs of the estrous cycle and pregnancy. Specifically, intracellular 
signaling, cytokine production, and cell death were evaluated.
Materials & Methods 
Reagents
Plastic culture vessels were purchased from Corning, Inc. (Corning, NY) and 
Becton-Dickinson (Franklin Lakes, NJ). NUNC-lmmuno MaxiSorp 96-well ELISA 
plates were purchased from Nalge Nunc (Rochester, NY). Microvascular 
endothelial cell medium (EGM-2MV) was obtained from Cambrex Bioscience 
(Walkersville, MD). Minimum Essential Medium Eagle (MEM), Hanks’ Balanced
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Salts (HBSS), fetal bovine serum (FBS), 0.25% trypsin/0.2% EDTA, FITC-labeled 
BS-I and ConA, a-D-galactose, a-D-glucose, monoclonal anti-p-actin, and 
protease and phosphatase I & II inhibitor cocktails were purchased from Sigma 
(St. Louis, MO). Gentamicin was obtained from Invitrogen (Carlsbad, CA). HRP- 
linked anti-rabbit IgG was purchased from Cell Signaling Technology (Danvers, 
MA). Interferon regulatory factor 1 (IRF-1) and inhibitor kappa B alpha (kB a ) 
antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Enhanced chemiluminescence reagent kit (ECL) was from Amersham 
Biosciences (Piscataway, NJ). Recombinant murine TNF was purchased from 
United States Biological (Swampscott, MA). Recombinant bovine IFNG and 
bovine TNF screening sets were purchased from Pierce Biotechnology 
(Rockford, IL). Human monocyte chemoattractant protein 1 (CCL2) DuoSet 
ELISA Development System was from R&D Systems (Minneapolis, MN). APO- 
BrdU Assay was purchased from Phoenix Flow Systems Inc. (San Diego, CA). 
Etanercept was a gift from Dr. Bo R. Rueda. All remaining reagents and 
materials were purchased from Sigma, VW R International, Inc. (West Chester, 
PA), or Fisher Scientific (Pittsburg, PA).
Cell Culture
Aliquots of purified CLENDOs of midcycle (day 12) and early pregnancy (day 60), 
isolated as previously described [48], were used in all experiments. The cells 
were cultured in EGM-2 MV with 3% FBS, growth factors [recombinant long R 
insulin-like growth factor-1, recombinant human fibroblast growth factor-B,
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recombinant human vascular endothelial growth factor, recombinant human 
epidermal growth factor, hydrocortisone, ascorbic acid, *Note: exact 
concentrations of growth factors are proprietary information*, antibiotic (30 pg/ml 
gentamicin sulfate), and antifungal (15 ng/ml amphotericin-B)] in a 37°C 
humidified incubator of 95% air and 5% C 0 2. Bovine pulmonary arterial 
endothelial cells (BPAECs) were cultured in MEM with 10% FBS and 20 pg/ml 
gentamicin in a 37°C humidified incubator of 95% air and 5% C 0 2.
Lectin Binding Experiments
CLENDOs of midcycle (passage 5) and early pregnancy (passage 5) were 
seeded at a density of 30,000 cells/ml in T25 flasks. At confluence, cells were 
removed from each flask by enzymatic treatment using HBSS modified with 2 
mM EDTA and 0.25% trypsin with 0.2% EDTA. The cell suspensions were spun 
at 200 x g for 10 min by centrifugation, counted using trypan blue dye exclusion, 
and concentrated at 400,000 cells/ml. One ml of the cell suspension was placed 
into five 12 x 75 mm polystyrene round bottom test tubes and centrifuged at 250 
x g for 10 min. Cell pellets were resuspended and incubated with 100 pi PBS 
(control) or FITC-labeled BS-I or ConA at a concentration of 2.5 pg/ml for 1 h at 
4°C. Additional controls included samples containing the competing sugar to BS- 
I and ConA (200 mM a-D-galactose and a-D-glucose, respectively) [172]. After 
the 1 h incubation, cells were rinsed with HBSS modified with 2 mM EDTA and 
centrifuged for 10 min at 250 x g. Cell pellets were then fixed by resuspension in 
375 pi PBS and 125 pi 4% paraformaldehyde (1% final concentration). The fixed
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cells were placed on 12 x 75 mm cell strainer (35 pm) capped polystyrene round 
bottom test tubes and centrifuged for 5 min at 200 x g in preparation for flow 
cytometric analysis. The cells were analyzed using a four-color, dual-laser 
FACSCalibur machine (BD Biosciences, Palo Alto, CA) and data were collected 
using Cellquest (BD Biosciences, Palo Alto, CA). Mean fluorescence lectin 
binding was calculated using WinMDI software (Joseph Trotter, Scripps 
Research Institute). BPAECs (200,000 cells/ml) were used as a positive control 
for comparative purposes [180,181],
Cytokine-stimulated Intracellular Signaling Experiments 
TNF-induced Degradation of IfcBa
CLENDOs of midcycle (passage 6) and early pregnancy (passage 6) were 
seeded at a density of 30,000 cells/ml and cultured in 6-well plates to confluence 
(1-2 weeks). Prior to cytokine treatment, cells were equilibrated in pre-warmed, 
gassed, basal medium (EBM-2) for 2 h. CLENDO cultures were exposed in 
duplicate to vehicle (control) or TNF (50 ng/ml) for 15 min. After cytokine 
treatment, the cells were placed on wet ice to terminate the experiment. The 
conditioned medium was removed and the cells rinsed with cold PBS and then 
lysed using a lysis buffer (20 mM Tris HCI pH 7 .4 ,150  mM NaCI, 1 mM EDTA, 1 
mM EGTA, 1% Triton X-100) containing protease and phosphatase I & II inhibitor 
cocktails. The cell lysates were sonicated for 5 sec and concentrated to 30-40 
pg protein. k B a  degradation was quantified by western blot analysis using an 
hcBa (C-21) primary antibody.
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Cytokine-induced IRF-1
CLENDOs of midcycle (passage 5) and early pregnancy (passage 7) were 
cultured in 6-well plates to confluence. Prior to cytokine treatment, fresh medium 
was applied to the cells. CLENDO cultures were exposed in duplicate to vehicle 
(control), TNF (50 ng/ml), TNF + etanercept (10 pg/ml, 30 min pre-treatment), 
IFNG (30 ng/ml), IFNG + etanercept, TNF + IFNG, or TNF + IFNG + etanercept 
for 90 min or 48 h. After cytokine treatment, the cells were placed on wet ice to 
terminate the experiment. Conditioned medium was removed and the cells were 
rinsed, lysed, and sonicated as described above. IRF-1 was quantified by 
western blot analysis using an IRF-1 (C-20) primary antibody.
Western Blot Analysis
Protein samples (30-40 pg) were subjected to 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and electrically transferred (75 
V for 2 h) to polyvinylidine difluoride (PVDF) membranes. Non-specific binding 
was blocked with 5% fat-free milk in TBST (Tris-Buffered Saline Tween-20: 50 
mM Tris HCI pH 7.5, 0.15 M NaCI, 0.05% Tween-20) at room temperature for 1 
h. Membranes were probed with primary antibodies Ik B oc (C-21) or IRF-1 (C-20) 
used at dilutions of 1:1000 with 5% fat-free milk in TBST overnight at 4°C. Four 5 
min washes with TBST were performed prior to membrane incubation with an 
anti-rabbit peroxidase conjugated IgG used at a 1:2000 dilution for 1 h.
Following four washes with TBST, bound antibody was detected using ECL 
detection reagents according to the manufacturer’s instructions. The blots were
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then exposed for 1-10 min using the Kodak Image Station 440 to determine band 
intensities., p-actin (1:5000) was used as an internal control to normalize the 
data.
IFNG-induced TNF Secretion
CLENDOs of midcycle (passage 6) and early pregnancy (passage 7) were 
seeded at a density of 30,000 cells/ml in 24-well plates and grown to confluence. 
Prior to cytokine treatment, fresh medium was applied to the cells. EC were 
exposed in duplicate to vehicle (control) or IFNG (30 ng/ml or 300 ng/ml) for 24 
or 48 h. Upon completion of the time points, conditioned medium was collected 
and TNF in the conditioned medium was measured using an enzyme-linked 
immunosorbent assay (ELISA).
Cytokine-induced CCL2 Secretion
CLENDOs of midcycle (passage 5) and early pregnancy (passage 7) were 
cultured in 6-well plates to confluence. Prior to cytokine treatment, fresh medium 
was applied to the cells. CLENDO cultures were exposed in duplicate to vehicle 
(control), TNF (50 ng/ml), TNF + etanercept (10 pg/ml, 30 min pre-treatment), 
IFNG (30 ng/ml), IFNG + etanercept, TNF + IFNG, or TNF + IFNG + etanercept 
for 48 h. Upon termination of the experiments, conditioned medium was 
collected. Secretion of CCL2 into culture medium was measured using ELISA.
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Immunoassays
TNF
TNF secretion from CLENDOs was measured using a commercially available 
sandwich ELISA specific for bovine TNF (Pierce Biotechnology, Inc.). All 
samples were run in duplicate in 96-well plates at a volume of 100 pi conditioned 
medium/well. A standard curve was created using recombinant bovine TNF at 
concentrations ranging from 39 pg/ml to 2500 pg/ml. The detection limit of the 
assay was 29.13 pg/ml and the mean interassay coefficient of variation was 7%. 
Results are expressed as pg of TNF per ml of conditioned medium.
CCL2
CCL2 secretion from CLENDOs was measured using a commercially available 
sandwich ELISA specific for human CCL2 (R&D Systems). Use of this assay kit 
for the measurement of bovine CCL2 has previously been validated [182], and 
verified [48, 82], All samples were run in duplicate in 96-well plates at a volume 
of 100 pi conditioned medium/well. A standard curve was created using 
recombinant human CCL2 at concentrations ranging from 15.6 pg/ml to 1000 
pg/ml. The detection limit of the assay was 1.84 pg/ml and the mean interassay 
coefficient of variation was 6%. Results are expressed as pg of CCL2 per ml of 
conditioned medium.
Cytokine-induced Cell Death
CLENDOs of midcycle (passage 5) and early pregnancy (passage 7) were 
seeded at a density of 30,000 cells/ml in 6-well plates and cultured to confluence.
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Along with fresh medium, EC were exposed to vehicle (control), TNF (50 ng/ml), 
IFNG (30 ng/ml), or TNF + IFNG for 48 h. For qualitative analysis, numbers of 
attached cells in 3 fields of view per well were counted. For quantitative analysis, 
cells were removed after 48 h by brief enzymatic treatment using HBSS modified 
with 2 mM EDTA and 0.25% trypsin with 0.2% EDTA. The cell suspensions were 
spun at 200 x g for 10 min by centrifugation, and the supernatant was removed 
using the pour and dab method. The cell pellets were resuspended in 500 pi 
HBSS and placed on 12 x 75 mm cell strainer (35 pm) capped polystyrene round 
bottom test tubes and centrifuged for 5 min at 200 x g. The strained cells were 
fixed using 500 pi of 2% paraformaldehyde (1% final concentration). The cells 
were fixed in the dark at 4°C for 45 min. After fixation, the cells were spun down 
at 200 x g for 10 min, supernatant removed, and then taken through two PBS 
washes. After the washes, the cell pellets were resuspended in 1 ml cold 70% 
ethanol and stored at -20°C. Quantification of apoptotic cells was determined 
using a modified terminal deoxynucleotide transferase dUTP nick end labeling 
(TUNEL) assay, APO-Brdll, according to the manufacturer’s instructions. Briefly, 
PRB-1 antibody (anti-Brdll) conjugated to Alexafluor 647 quantified breaks in 
cellular DNA, and propidium iodide staining measured DNA content. Cells of the 
human lymphoma line, HL-60, supplied by the manufacturer, were used as 
positive and negative controls, in which cells were either untreated (negative) or 
treated to induce apoptosis (positive). Cell death was measured using a four- 
color, dual-laser FACSCalibur machine. Data were collected using Cellquest and 
analyzed using WinMDI software.
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Statistical Analyses
Results were analyzed by two-sample T-test, paired T-test, or by ANOVA using 
the general linear model procedure of Minitab (State College, PA) or Systat 
(Point Richmond, CA) followed by a Tukey’s multiple comparison test. The 
results are expressed as mean + SEM and represent three independent 
experiments. A p-value of less than 0.05 was considered significant.
Results 
Lectin Binding of CLENDOs
Results of previous studies indicate lectin binding differs among endothelial cells 
of the bovine CL depending upon reproductive status and phenotype [172]. The 
present experiments were conducted to further assess lectin binding in CLENDO  
cultures derived from CL of the estrous cycle and pregnancy (Figs. 4 & 5). Flow 
cytometric analysis of FITC-labeled lectins revealed comparable BS-I (Fig. 4) and 
ConA (Fig. 5) binding of CLENDOs of the estrous cycle and pregnancy. 
Specificity of lectin binding was demonstrated in all cases except one (BS-I on 
CLENDOs of pregnancy) by inhibition with the appropriate competing sugar (P < 
0.05, Figs. 4 & 5).
Verification of Lectin Binding
Lectin binding of BS-I and ConA was also assessed in BPAECs as a positive 
control (Fig. 6) [180, 181], Binding of ConA was greater than BS-I in these 
macrovascular endothelial cells (P < 0.05). As above, specificity of lectin binding
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for both BS-I and ConA was demonstrated by displacement with a-D-galactose 
and a-D-glucose, respectively (P < 0.05, Fig. 6).
TNF Induces Degradation of licBa
Cultures of CLENDOs exposed to TNF had substantial degradation of licBa (P < 
0.05), but there was no difference in Ik B oc degradation attributed to reproductive 
status (P > 0.05, Fig. 7).
TNF and IFNG Induce IRF-1 Expression
In cultures of CLENDOs, TNF induced a robust increase in IRF-1 (P < 0.05, Fig.
8) as did IFNG (P < 0.05, Fig. 9). There was no difference in cytokine-induced 
IRF-1 expression, however, attributed to reproductive status (P > 0.05, Figs. 8 &
9).
IFNG Induces TNF Secretion by CLENDOs
Conditioned medium from the cultures revealed a dose-dependent increase in 
TNF secretion by CLENDOs of the estrous cycle and pregnancy in response to 
IFNG stimulation (P < 0.05, Fig. 10). However, there was no difference in TNF  
production by CLENDOs attributed to reproductive status (P > 0.05, Fig. 10).
IFNG and TNF Induce CCL2 Secretion by CLENDOs
Conditioned medium from the cultures also revealed an increase in CCL2 
secretion by CLENDOs of the estrous cycle and pregnancy in response to TNF
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and IFNG stimulation alone and in combination (P < 0.05, Fig. 11). Again, 
however, there was no difference in CCL2 production by CLENDOs based upon 
reproductive status (P > 0.05, Fig. 11).
Etanercept Inhibits CCL2 Production and IRF-1 Expression Induced by 
TNF, but not IFNG
Etanercept is a synthetic, soluble TNF receptor that functions as a TNF 
antagonist [183]. In cultures of CLENDOs, etanercept diminished TNF-induced 
CCL2 production by CLENDOs (P < 0.05), but had no effect on IFNG- or TNF + 
IFNG-induced CCL2 secretion (P > 0.05, Fig. 11). Reproductive status of the 
cow did not alter CLENDO responsiveness (P > 0.05, Fig. 11). Etanercept also 
inhibited IRF-1 expression by TNF and TNF + IFNG following a 90 min treatment 
period (P < 0.05, Fig. 12b), but had no effect on IFNG-induced IRF-1 expression 
(P > 0.05, Fig. 12b). There was no difference in etanercept inhibition of IRF-1 in 
CLENDOs attributed to reproductive status at 90 min (P > 0.05, Fig. 12b). 
However, etanercept failed to inhibit cytokine-induced IRF-1 expression following 
a 48 h treatment period (Fig. 12d), and IRF-1 expression was greater in 
CLENDOs of the estrous cycle (P < 0.05, Fig. 12d).
Cytotoxic Effect of TNF on CLENDOs of the Estrous Cycle
The cytokines TNF and TNF + IFNG are cytotoxic to CLENDOs of pregnancy 
[139]. In the current study, cytokines had a similar effect on CLENDOs of the 
estrous cycle. That is, IFNG alone failed to induce cell death, but TNF and TNF
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+ IFNG induced death in approximately 30% and 10% of the cells based upon 
visual observation (Fig. 13) and quantification of APO-BrdU labeling by flow 
cytometric analysis (Fig. 15), respectively.
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Figure 4. BS-I lectin binding of CLENDOs of the estrous cycle and pregnancy as
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BS-I BS-l+galactose
Representative flow cytometric 
histogram of BS-I binding in 
CLENDOs (Fig. 4a). A right shift 
along the x-axis indicates 
increased lectin binding of FITC- 
labeled BS-I. Addition of the 
competing sugar, a-D-galactose, 
displaced lectin binding, yielding 
a shift equivalent to controls.
The geometric mean 
fluorescence of the histograms 
was extrapolated and is 
presented as bars + SEM, n=3 
experiments (Fig. 4b). BS-I 
binding was increased, but 
comparable in CLENDOs of 
midcycle CL and CL of 
pregnancy (P > 0.05). Different 
letters denote significant 
differences in lectin binding 
among the treatments and cell 
types (P < 0.05).
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Figure 5. ConA lectin binding of CLENDOs of the estrous cycle and pregnancy as
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Representative flow cytometric 
histogram of ConA binding in 
CLENDOs (Fig. 5a). A right shift 
along the x-axis indicates 
increased lectin binding of FITC- 
labeled ConA. Addition of the 
competing sugar, a-D-glucose, 
displaced lectin binding, yielding 
a shift equivalent to controls.
The geometric mean 
fluorescence of the histograms 
was extrapolated and is 
presented as bars + SEM, n=3 
experiments (Fig. 5b). ConA 
binding was increased, but 
comparable in CLENDOs of 
midcycle CL and CL of 
pregnancy (P > 0.05). Different 
letters denote significant 
differences in lectin binding 
among the treatments and cell 
types (P < 0.05).
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Representative flow cytometric 
histogram of BS-I (Fig. 6a) and 
ConA (Fig. 6b) binding in 
BPAECs. Similar 
characteristics of lectin binding 
and displacement were 
observed in macrovascular 
endothelial cells. Bars 
represent mean fluorescence + 
SEM, n=3 experiments (Fig. 
6c). Different letters denote 
significant differences in lectin 
binding among the treatments 
and cell types (P < 0.05).
BS-l+galactose ConA ConA+glucose
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control TNF control TNF
Representative western blot (Fig. 7a) and bar graph (Fig. 7b) depicting TNF-induced 
Ik Boc degradation in CLENDOs. Within 15 minutes of exposure to TNF, CLENDOs 
exhibited a 5-fold decrease in Ik Bcc (P < 0.05). CLENDOs of midcycle did not differ from 
CLENDOs of pregnancy with respect to the effect of TNF (P > 0.05). Bars represent 
relative intensity of hcBa normalized to p-actin + SEM (n=3 experiments). Different 
letters denote significant differences in kBa degradation among the treatments and cell 
types (P < 0.05).
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Figure 8b.
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Representative western blot (Fig. 8a) and bar graph (Fig. 8b) depicting TNF-induced 
IRF-1 expression in CLENDOs. Within 90 minutes of exposure to TNF, CLENDOs 
exhibited a 4-fold increase in IRF-1 expression (P < 0.05). CLENDOs of midcycle did 
not differ from CLENDOs of pregnancy with respect to the effect of TNF (P > 0.05). Bars 
represent relative intensity of IRF-1 normalized to p-actin + SEM (n=3 experiments). 
Different letters denote significant differences in IRF-1 expression among the treatments 
and cell types (P < 0.05).
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control IFNG control IFNG
Representative western blot (Fig. 9a) and bar graph (Fig. 9b) depicting IFNG-induced 
IRF-1 expression in CLENDOs. Within 90 minutes of exposure to IFNG, CLENDOs 
exhibited a 14-fold increase in IRF-1 expression (P < 0.05). CLENDOs of midcycle did 
not differ from CLENDOs of pregnancy with respect to the effect of IFNG (P > 0.05). 
Bars represent relative intensity of IRF-1 normalized to p-actin + SEM (n=3 
experiments). Different letters denote significant differences in IRF-1 expression among 
the treatments and cell types (P < 0.05).
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TNF secretion by CLENDOs of the estrous cycle and pregnancy in culture over a 48 h 
treatment period as determined by ELISA of conditioned culture medium. Response to 
IFNG at 30 ng/ml and 300 ng/ml is shown. Overall response to IFNG did not differ 
between CLENDOs of the estrous cycle and pregnancy (P > 0.05). Bars represent 
mean protein secretion + SEM (n=3 experiments). Different letters denote differences in 
TNF protein secretion among the treatments and cell types (P < 0.05).
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CCL2 secretion by CLENDOs of the estrous cycle and pregnancy in culture over a 48 h 
treatment period as determined by ELISA of conditioned culture medium. Responses to 
the cytokines TNF and IFNG, and the TNF antagonist, etanercept, are shown. Overall 
response to cytokines did not differ between CLENDOs of the estrous cycle and 
pregnancy (P > 0.05). Bars represent mean protein secretion + SEM (n=3 experiments). 
Different letters denote differences in CCL2 protein secretion among the treatments and 
cell types (P < 0.05).
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Figure 12. Effect of etanercept on cytokine-induced IRF-1 expression in CLENDOs of
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Representative western blot (Fig. 12a) and bar graph (Fig. 12b) depicting cytokine- 
induced IRF-1 expression in CLENDOs of the estrous cycle and pregnancy over a 90 min 
treatment period. Responses to the cytokines TNF and IFNG, and the TNF antagonist, 
etanercept, are shown. Overall response to cytokines did not differ between CLENDOs of 
the estrous cycle and pregnancy (P > 0.05). Bars represent relative intensity of IRF-1 
normalized to p-actin + SEM (n=3 experiments). Different letters denote significant 
differences in IRF-1 expression among the treatments and cell types (P < 0.05).
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Representative western blot (Fig. 12c) and bar graph (Fig. 12d) depicting cytokine- 
induced IRF-1 expression in CLENDOs of the estrous cycle and pregnancy over a 48 h 
treatment period. Responses to the cytokines TNF and IFNG, and the TNF antagonist, 
etanercept, are shown. Overall response to cytokines differed between CLENDOs of the 
estrous cycle and pregnancy (P < 0.05). Bars represent relative intensity of IRF-1 
normalized to p-actin + SEM (n=3 experiments). Different letters denote significant 
differences in IRF-1 expression among the treatments and cell types (P < 0.05).
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Figure 13. Qualitative cytokine-induced cell death in CLENDOs of the estrous cycle.
control IFNG TNF + IFNG
Cytokine-induced cell death in CLENDOs of the estrous cycle over a 48 h treatment 
period. Responses to the cytokines TNF and IFNG are shown. IFNG failed to induce 
cell death in CLENDOs from midcycle CL. Conversely, TNF and TNF + IFNG resulted in 
approximately 60% death (P < 0.05). Bars represent percentage of viable cells + SEM 
(n=3 experiments). Different letters denote differences in cell death among the 
treatment groups (P < 0.05).
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Figure 14. Cytokine-induced cell death visual observations.
Figure 14a. Figure 14b.
Control IFNG
Figure 14c. Figure 14d.
TNF TNF + IFNG
Representative phase-contrast photomicrographs (25x magnification) of midcycle 
CLENDO cultures following 48 h of the indicated treatments (Fig. 14). Yellow boxes 
highlight areas affected by the corresponding treatments. Control cells display 
cobblestone morphology, with the monolayer intact (Fig. 14a). IFNG-treated cells 
display large, flattened, senescent-like cells between areas of intact monolayer (Fig. 
14b). TNF treatment resulted in characteristic signs of death, including the obvious 
reduction in attached cells (Fig. 14c). Finally, TNF + IFNG treatment resulted in similar 
effects seen with TNF alone, with fewer cells attached to the cultureware (Fig. 14d).
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Figure 15. Quantitative cytokine-induced cell death in CLENDOs of the estrous cycle.
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Cytokine-induced cell death in CLENDOs of the estrous cycle over a 48 h treatment 
period. Responses to the cytokines TNF and IFNG are shown as representative flow 
cytometric density plots of TUNEL labeling in CLENDOs (Fig. 15a). A shift in the cell 
population to the right indicates increased TUNEL label/apoptosis. The percentage of 
apoptotic cells was extrapolated and is represented as bars + SEM, n=3 experiments (Fig. 
15b). IFNG failed to induce cell death, but TNF and TNF + IFNG resulted in approximately 
15% and 10% death, respectively. However, there was no difference in cell death among 
the treatment groups (P > 0.05).
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Discussion
In the present study, structural and functional characteristics of CLENDOs 
of the estrous cycle and pregnancy were compared to elucidate the influence of 
reproductive status on the diversity of the luteal micro vasculature. We 
determined CLENDOs of the estrous cycle and pregnancy have similar 
properties of lectin binding and responsiveness to the cytokines TNF and IFNG. 
Specifically, the extent of BS-I and ConA binding was comparable in CLENDOs 
of the estrous cycle and pregnancy. TNF induction of k B a  degradation, IRF-1 
production, and cell death were likewise similar in CLENDOs of the estrous cycle 
and pregnancy. IFNG stimulated IRF-1 production and, in combination with TNF, 
induced apoptosis in CLENDOs of the estrous cycle and pregnancy. In addition, 
these studies provide the first convincing evidence that CLENDOs are a source 
of TNF production, but this phenomenon was not influenced by reproductive 
status of the cow. Collectively, these results indicate that microvascular 
endothelial cells of the bovine CL do not change morphologically or functionally 
throughout the estrous cycle and early pregnancy. These findings are significant 
because previous studies have reported or alluded to physiological distinctions 
between the CL of the estrous cycle and of pregnancy.
Binding of the lectins BS-I and ConA were detected by flow cytometric 
analysis of CLENDOs of the estrous cycle and pregnancy and revealed relatively 
equal mean fluorescence intensities. Determining lectin binding properties of 
these cell types is important because BS-I is an accepted endothelial cell marker 
which has been used extensively in magnetic bead isolation of CLENDOs for in
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vitro experimentation [62, 167, 168, 170, 171]. Lectin binding to endothelial cells, 
however, is species, age, organ, and vascular bed specific [173]. BS-I is 
considered a constitutive endothelial cell marker throughout the developmental 
stages of the corpus luteum [20], but others indicate that BS-I expression is more 
ubiquitous, with BS-I binding found in an array of bovine cell types including 
epithelial cells, endothelial cells, smooth muscle cells, thymocytes, and 
fibroblasts [184], These observations indicate BS-I potentially binds other cell 
types within the CL and not exclusively endothelial cells, as previously suggested 
[173]. Thus, magnetic bead isolation of CLENDOs based upon BS-I binding 
might not be an ideal approach for obtaining pure cultures of CLENDOs, as it has 
the potential to introduce other, contaminating cell types into the culture.
In one previous study, Plendl et al. (1996) reported differences in lectin 
binding between CLENDOs of the estrous cycle and pregnancy and among 
CLENDO phenotypes [172]. Two distinct cell types derived from the estrous 
cycle and pregnancy were described: cobblestone and arcuate morphology.
Using flow cytometric analysis, the authors found BS-I binding to both 
cobblestone and arcuate CLENDOs of pregnancy upregulated (~2-fold) as 
compared to the same cell types of the estrous cycle. Furthermore, BS-I binding 
to cobblestone endothelial cells is approximately 3-fold greater than arcuate 
endothelial cells from CL of pregnancy. In contrast, binding of BS-I to the 
cobblestone cell type in CL of the estrous cycle is approximately 1.5-fold less 
than the arcuate phenotype [172]. Collectively, these results indicate differences 
in lectin binding based on reproductive status and phenotype. In the current
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study, we found no difference in lectin binding due to reproductive status. The 
disparity between our results and those of Plendl and co-workers (1996) might be 
due to differences in experimental methods. For instance, the cell types utilized 
in the current investigation were both cobblestone and arcuate morphology, and 
presumably constitute the predominant phenotypes of endothelial cells within the 
bovine CL. Plendl et al. (1996) used specific phenotypes as previously described 
by Spanel-Borowski and van der Bosch (1990) [70], If specific morphologic 
phenotypes have indeed higher lectin binding than others as Plendl et al. (1996) 
suggest, then a mixture of the predominant phenotypes might mask substantial 
differences in lectin binding for a particular cell type. Further quantitative 
analysis of lectin binding will be needed to clarify specificity in CLENDOs, not 
only because of the emerging use of lectins in magnetic bead isolation, but also 
because of their role in cell-cell interactions. Hyperglycosylation or upregulation 
of lectin binding on endothelial cells has emerged as a mechanism of cell 
migration in bovine aortic endothelial cells [173], Migrating endothelial cells 
precede proliferation of endothelial cells during angiogenesis. Upregulation of 
lectin binding is considered important in these cell-cell interactions, particularly 
with other endothelial cells or immune cells, especially in the context of 
inflammatory processes [20, 173].
BPAECs were used in the current experiments as a positive control for 
BS-I and ConA binding, as documented by others [180, 181]. The BPAECs 
display higher mean fluorescence intensity than CLENDOs. The difference in 
lectin binding could be due to innate differences in the macrovasculature versus
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microvasculature, or a difference in cell numbers used in the experiments. The 
BPAECs were analyzed for lectin binding at a concentration of -200,000 cells/ml, 
whereas the CLENDOs were analyzed at -400,000 cells/ml. Considering the 
same concentration of FITC-labeled lectin was used for each cell type, the 
BPAECs could have been oversaturated with FITC-labeled lectin, revealing a 
higher binding capacity. Additionally, ConA binding was higher than BS-I in 
BPAECs. This is not unexpected, as there is documentation alluding to a higher 
binding capacity for ConA compared to BS-I in BPAECs, based upon lectin 
affinity chromatography [180].
The endothelium is a major target for cytokines in most tissues and is 
pivotal to immune processes, particularly inflammation. Endothelial cells serve 
as part of the barrier between the blood stream and the tissues, determining the 
traffic and action of cells and molecules within the body [81]. Knowing that large 
numbers of endothelial cells compose the CL [17], endothelial cells and their 
responsiveness to cytokines are reasoned to be important in luteal regression. 
Here, intracellular signaling pathways of CLENDOs induced in response to TNF  
and IFNG stimulation were investigated. Nuclear factor kappa B (NF-kB) 
activation, via IkBoc degradation, and IRF-1 were induced equally in CLENDOs of 
the estrous cycle and pregnancy. Others have noted similar signaling events of 
TNF and IFNG in bovine steroidogenic cells [112], but this is the first study, to our 
knowledge, investigating these aspects of cytokine signaling in bovine 
CLENDOs.
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Activation of the NF-kB signaling pathway stimulates the production of 
proinflammatory mediators, such as TNF and CCL2 [123,185], possibly 
contributing to immune mediated events during luteal regression. In the current 
study, TNF-induced k B a  degradation indicates NF-kB activation in both cell 
types, revealing that proinflammatory pathways are equally inducible during the 
estrous cycle and pregnancy. Likewise, TNF-induced IRF-1 expression further 
validates NF-kB activation in both cell types, as IRF-1 induction is mediated by 
NF-kB [96]. IRF-1 expression is also mediated by signal transducers and 
activators of transcription (Stat). Therefore, IFNG, which signals through the 
Janus kinase (Jak)-Stat pathway, is a potent inducer of IRF-1 [84]. In the current 
study, CLENDOs of the estrous cycle and pregnancy equally expressed IRF-1 
following stimulation with IFNG. IRF-1 regulates the transcription of IFNG- 
responsive genes, such as MHC expression [103]. In fact, IFNG induces the 
expression of MHC class II molecules on bovine luteal steroidogenic cells [109] 
and CLENDOs [110]. Also, IFNG increases the expression of TNF receptors on 
the surface of cells [93, 94], The role of IRF-1 in these actions of IFNG is not 
known, but based on our observations and those of Suter and co-workers (2001) 
[112], IFNG and/or TNF activation of IRF-1 might induce these effects in the CL, 
thus contributing to immune-mediated events during luteal regression.
One culminating effect of cytokines in CLENDOs is the onset of apoptosis. 
Apoptotic death in CLENDOs of pregnancy induced by TNF alone and in 
combination with IFNG has been documented [139], An incidence of 30% death 
and 50% death was reported following TNF and TNF + IFNG treatment,
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respectively [139]. In the present study, cytokine-induced apoptosis of 
CLENDOs of the estrous cycle was measured both qualitatively and 
quantitatively. Our visual observations were similar to those reported by Pru and 
co-workers (2003) [139] for CLENDOs of pregnancy in that TNF resulted in 
significant death (-60% ). However, TNF + IFNG did not increase the incidence 
of death. Instead, IFNG provoked a morphological change in the cells, with little 
to no death, and more enlarged, senescent-like cells. Similar observations 
following IFNG treatment have been reported by others [72, 73]. The 
combination of a morphological change in the cells along with the appearance of 
senescent-like cells indicates that IFNG may have an overall negative influence 
on CLENDOs without resulting in apoptosis. IFNG could possibly alter the 
metabolic activity of the cells, particularly decreasing it, resulting in a cytostatic 
culture. This would explain the anti-proliferative nature of the cells and the lack 
of death.
Quantitative analysis of cytokine-induced death by TUNEL assay and flow 
cytometric analysis yielded results of less cell death than our visual observations. 
TNF induced approximately 15% death, while TNF + IFNG induced 
approximately 10% death. TUNEL staining was used to identify strand breaks in 
DNA, the final step in the apoptotic process. Cells undergoing apoptosis (i.e. 
increased caspase production) but not to the point of DNA degradation, would 
not be detected by the TUNEL assay. Thus, our cytometric results are a 
conservative measure of cell death as compared to the more subjective measure 
of visual assessment. Moreover, flow cytometric analysis of TUNEL staining
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eliminates any subjective bias of visual counting of TUNEL-positive dead cells. 
Given these considerations, the conservative estimate of cytokine-induced 
apoptosis of CLENDOs in the current study is not surprising.
Understanding the mechanisms of TNF receptor signaling could be key to 
understanding the apoptotic actions of TNF and TNF + IFNG on CLENDOs.
TNF, via TNF receptor 1, signals through both pro- and anti-apoptotic pathways 
[121]. Ligand binding induces the activation of death domain associated 
proteins, such as caspases, while also inducing the activation of NF-kB- 
associated anti-apoptotic proteins such as cellular FLICE-like inhibitory protein 
(cFLIP), B-cell leukemia/lymphoma 2 (Bcl-2), and cellular inhibitor of apoptosis 
protein-1 (clAP-1) [121]. Inhibition of NF-kB activity by proteins such as IRF-1 
leads to increased cellular susceptibility to TNF-induced apoptosis [121]. TNF 
and IFNG independently and synergistically promote the expression of IRF-1 
[152]. IRF-1 inhibits NF-kB mediated activation of cell survival signals through 
modulation of NF-kB transcriptional activity [106]. Therefore, IRF-1 induction by 
TNF and IFNG could inhibit the anti-apoptotic NF-kB pathway, resulting in cell 
death/apoptosis. In the present study, TNF and IFNG alone and in combination 
induced IRF-1 expression in CLENDOs, but there was no effect attributable to 
reproductive status. The ability of TNF and IFNG to activate signaling pathways 
in CLENDOs of the estrous cycle and pregnancy that result in IRF-1 expression 
could explain the noted increase in death seen with TNF + IFNG as compared to 
TNF alone by Pru and co-workers (2003) [139]. With TNF alone, both pro- and 
anti-apoptotic pathways become activated, resulting in some limited cell death.
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Conversely, with TNF + IFNG, the pro-apoptotic pathway prevails. The 
synergistic increase in IRF-1 expression decreases the activation of the anti- 
apoptotic NF-kB pathway, thereby inhibiting production of anti-apoptotic proteins, 
and increasing the extent of cell death. Measuring the expression of anti- 
apoptotic proteins under similar cytokine treatments could provide insight into this 
paradigm.
The cellular source(s) of TNF within the CL has been debated for a 
number of years. Hehnke-Vagnoni and co-workers (1995) localized TNF to 
endothelial cells of the porcine CL, stating that macrophages are rarely evident 
and not associated with TNF production [126]. In contrast, Zhao and co-workers 
(1998) identified macrophages as the major source of TNF within the porcine CL, 
finding that endothelial cells consistently lacked TNF staining [127]. For both 
studies, the basis of TNF assessment utilized immunohistochemistry and/or TNF 
bioassay. Neither study measured TNF production by quantitative immunoassay 
using purified cell preparations. The present study used a bovine TNF ELISA to 
determine TNF production by CLENDOs of the estrous cycle and pregnancy. 
Under the stimulation of IFNG, both cell types dose-dependently produced an 
equivalent amount of TNF. This study is the first to quantify TNF production by 
endothelial cells of the bovine CL. The implications of this production include the 
possible autocrine effect TNF may have on CLENDOs to influence cellular 
signaling and apoptosis. TNF receptors are localized to small luteal cells (small 
steroidogenic and endothelial cells) of the CL [130, 133] indicating that 
endothelial cells could produce TNF under IFNG stimulation and respond to TNF
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in an autocrine manner. These possibilities raise the question of whether or not 
some actions of IFNG are mediated through TNF pathways. W e assessed this 
possibility using a TNF antagonist, the synthetic soluble TNF receptor, 
etanercept [183].
Cytokine-induced CCL2 production by CLENDOs of pregnancy has been 
previously documented by our laboratory [48, 82], We have now determined that 
cytokine-induced CCL2 production also occurs in CLENDOs of the estrous cycle, 
and thus, is not affected by reproductive status. Etanercept did not affect IFNG- 
induced CCL2 production, suggesting that IFNG-induced production of CCL2 is 
not via an autocrine effect of TNF. Consistent with the results seen for CCL2, 
etanercept also did not alter IFNG-induced IRF-1 expression. The efficacy and 
specificity of etanercept was demonstrated by its ability to inhibit TNF-induced 
CCL2 production and IRF-1 expression. Together, these results indicate the 
actions of IFNG are not mediated through TNF pathways. However, the ability of 
etanercept to prevent TNF-induced signaling has important experimental 
implications for luteal regression. Future in vivo work, such as treating cows with 
etanercept, could be conducted to determine the effect of TNF inhibition during 
natural luteal regression.
Another interesting finding of the etanercept experiments was the outcome 
observed following treatment exposure time. Following a 90 min treatment 
period, etanercept inhibited TNF-induced IRF-1 expression, and there was no 
difference in IRF-1 expression due to reproductive status of the cow. However, 
following a 48 h treatment period, there was no significant inhibition of TNF-
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induced IRF-1 expression, and IRF-1 expression was greater in CLENDOs of the 
estrous cycle. Suter et al. (2001), using CLENDOs of pregnancy, did not detect 
TNF-induced IRF-1 expression at 24 or 48 h [112]. In contrast, not only was 
TNF-induced IRF-1 detected after 48 h in the current study, but there was an 
overall increase in IRF-1 expression due to reproductive status, with a trend 
toward greater IRF-1 expression in CLENDOs of the estrous cycle. It appears 
CLENDOs of the estrous cycle respond more readily to cytokines over an 
extended exposure period than CLENDOs of pregnancy. The reason for this is 
unknown, but perhaps CLENDOs of pregnancy establish mechanisms to tolerate 
systemic levels of cytokines and immune events associated with implantation 
and pregnancy.
The current study compared structural and functional characteristics of 
CLENDOs of the estrous cycle and CLENDOs of pregnancy. Our results indicate 
luteal microvascular endothelial cells do not drastically change, structurally or 
functionally, as the cells transition from the estrous cycle into pregnancy. 
However, initial disparities in the response of CLENDOs of the estrous cycle 
versus pregnancy regarding TNF- and TNF + IFNG-induced apoptosis could 
indicate potential differences in the susceptibility of these cells to mechanisms of 
apoptosis. Such mechanisms have important implications in understanding the 
adaptable existence of the luteal micro vasculature, and also in comprehending 
the basic processes of angiogenesis and angioregression. These observations 
are significant not only to reproduction and fertility, but also to our understanding 
of angiogenesis and angioregression for cancer research.
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